.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 5,676,930

« Back to Dashboard

Claims for Patent: 5,676,930

Title: Stabilized medicinal aerosol solution formulations
Abstract:Stabilized medicinal aerosol solution formulations comprising medicaments that degrade or decompose by interaction with solvents or water, an HFC propellant, a cosolvent and an acid are described. Further, specific medicinal aerosol solution formulations comprising ipratropium bromide or fenoterol, ethyl alcohol, 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoropropane, and either an inorganic acid or an organic acid are described. The acids are present in amounts sufficient to reduce the degradation of the medicaments to acceptable levels.
Inventor(s): Jager; Paul Donald (Waterbury, CT), Kontny; Mark James (New Milford, CT), Nagel; Jurgen Hubert (Ingelheim/Rhein, DE)
Assignee: Boehringer Ingelheim Pharmaceuticals, Inc. (Ridgefield, CT)
Application Number:08/475,060
Patent Claims: 1. An aerosol solution formulation comprising from about 0.001% to about 10% wt./wt. ipratropium bromide, a hydrofluorocarbon propellant, ethyl alcohol and an organic acid, said organic acid being selected from the group consisting of ascorbic acid and citric acid.

2. An aerosol solution formulation according to claim 1 wherein the hydrofluorocarbon propellant is 1,1,1,2-tetrafluoroethane.

3. An aerosol solution formulation according to claim 2 wherein the ethyl alcohol is within the range of about 1.0 to 50.0% wght./wght.

4. An aerosol solution formulation according to claim 1 wherein the organic acid is ascorbic acid and which is within the range of about 0.0045 to 5.0 mg/ml.

5. An aerosol solution formulation according to claim 1 wherein the organic acid is citric acid and which is within the range of about 0.0039 to 27.7 mg/ml.

6. An aerosol solution formulation according to claim 5 wherein the amount of ipratropium bromide is about 0.0187% wght./wght.

7. An aerosol solution formulation according to claim 5 wherein the amount of ipratropium bromide is about 0.0374% wght./wght.

8. An aerosol solution formulation according to claim 5 wherein the amount of ipratropium bromide is about 0.0748% wght./wght.

9. An aerosol solution formulation according to claim 1 wherein the hydrofluorocarbon propellant is 1,1,1,2,3,3,3-heptafluoropropane.

10. An aerosol solution formulation according to claim 9 wherein the ethyl alcohol is within the range of about 1.0 to 50.0% wght./wght.

11. An aerosol solution formulation according to claim 9 wherein the organic acid is ascorbic acid and which is within the range of about 0.0045 to 5.0 mg/ml.

12. An aerosol solution formulation according to claim 9 wherein the organic acid is citric acid and which is within the range of about 0.0039 to 27.7 mg/ml.

13. A method for stabilizing an aerosol solution formulation wherein the aerosol solution formulation comprises from about 0.001% to about 10% wt./wt. ipratropium bromide, 1,1,1,2-tetrafluoroethane and a cosolvent, said method comprising adding an organic acid selected from the group consisting of ascorbic acid and citric acid to said aerosol to stabilize the ipratropium bromide in the aerosol solution formulation.

14. A method for stabilizing an aerosol solution formulation wherein the aerosol solution formulation comprises from about 0.001% to about 10% wt./wt. ipratropium bromide, 1,1,1,2,3,3,3-heptafluoropropane and a cosolvent, said method comprising adding an organic acid selected from the group consisting of ascorbic acid and citric acid to said aerosol to stabilize said aerosol solution formulation.

15. A method of treatment according to claim 14 wherein the cosolvent is ethyl alcohol.

16. An aerosol solution formulation comprising a medicament, an HFC propellant, an organic cosolvent, and an inorganic acid, wherein the inorganic acid is present in an amount effective to provide chemical stability to the medicament in the formulation.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc